Clinical Lymphoma, Myeloma and Leukemia

Aims & Scope

Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia.

Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias.

The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia.

Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.7
2024	2.70

SJR (SCImago Journal Rank)

Year	Value
2024	0.513

Quartile

Year	Value
2024	Q3

h-index

Year	Value
2024	68

Journal Rank

Year	Value
2024	11352

Journal Citation Indicator

Year	Value
2024	1417

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections

  Citation: 269

  Authors: Carla, Jocelyn, Andrew D.

• Myeloid Sarcoma: Presentation, Diagnosis, and Treatment

  Citation: 185

  Authors: L. Max, Maria, Samuel J., David, Anant

• Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

  Citation: 144

  Authors: Rita, Hagop, Nicholas J., Naval, Koichi, Guillermo, Courtney, Jan, Jorge, Nitin, William, Salim, Marina, Elias

• Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm

  Citation: 131

  Authors: Elias, Hagop, Jorge

• Age, Race, Sex, Stage, and Incidence of Cutaneous Lymphoma

  Citation: 126

  Authors: Lynn D., Ginette A., James B.

• Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

  Citation: 124

  Authors: Maria-Victoria, Pieter, Vania, Ajay K., Jane A., Wolney, Paolo, Chang-Ki, Eva, Katja, Christopher, Jordan M., Himal, Xiang, Jon, Rachel, Andrew

• Nilotinib-Associated Vascular Events

  Citation: 116

  Authors: Alfonso, Hagop, Jorge

• Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval

  Citation: 110

  Authors: Hagop M., Susan, Jorge

• Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

  Citation: 107

  Authors: Stefan K., Jasmine, Alexander W., Sonali M., Jia, Henry C., Carlyn R., Yibin, R. Katherine, Essel, Eric A., Kerry S., Nadia, Rawat, Nathan H., Richard I., Yasuhiro

• Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

  Citation: 107

  Authors: Hervé, Heinz, Ola, Bruno, Chris, Hui, Kefei, Sunhee, Maria-Victoria

---